Condition category
Urological and Genital Diseases
Date applied
27/05/2013
Date assigned
05/06/2013
Last edited
05/06/2014
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Lay summary under review 2

Trial website

Contact information

Type

Scientific

Primary contact

Dr YoonGoo Kim

ORCID ID

Contact details

Samsung Medical Center
81 Irwon-Ro
Gangnam-gu
Seoul
135-710
Korea
South

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

1503

Study information

Scientific title

Assessment of plasma conductivity in Korean hemodialysis (HD) patients in relation to sodium and fluid status: a prospective, open-label, multicenter study

Acronym

Study hypothesis

To demonstrate in prevalent Korean anuric dialysis patients that the change in plasma conductivity during dialysis, as measured by the Diascan tool, is related to the weight gain during the following interdialytic period (inter-dialytic weight gain).

Ethics approval

1. Samsung Medical Center IRB : Approved on 07/02/2013 [SMC2012-12-099-001]
2. Kangbuk Samsung Medical Center IRB : Approved on 12/02/2013 [KBC13020D]
3.Catholic Univ. St'Mary Incheon Hospital IRB : Approved on 04/04/2013 [CIRB-00060_2-014]
4. Kangwon National Univ. Hospital IRB : Approved on 05/02/2013 [KWNUH2013-01-003-001]
5. Konkuk Univ. Chungju Hospital IRB : Approved on 19/02/2013 [2013-005]
6. Catholic Univ. St'Mary Daejeon hospital IRB : Approved on 04/04/2013 [CIRB-00060_2-013]
7. Hallym University Kangnam Sacred Heart Hospital IRB : Approved on 28/02/2013 [2013-01-11(701)]
8. Inje University Sanggye Baik Hospital IRB : Approved on 13/02/2013 [SPIRB-13-009]

Study design

Prospective open-label multicenter study

Primary study design

Observational

Secondary study design

Cohort study

Trial setting

Hospitals

Trial type

Treatment

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

End stage renal disease (ESRD)

Intervention

The patient will be on his/her ordinary dialysis schedule during the study period, and treatment parameters like session length, blood flow rate, dialyzer type and size, anticoagulation strategy, and ultrafiltration (UF) volume will be prescribed in the ordinary manner unaffected by the study. The subject’s prescribed dialysis fluid composition should preferably be kept unchanged during the study period.

In addition to the enrollment visit, patient and treatment data collection will be done in conjunction with 12 ordinary dialysis sessions. There are no extra visits besides the usual dialysis treatments.

Total Duration of study treatment : 6 weeks per patient

Intervention type

Other

Phase

Not Applicable

Drug names

Primary outcome measures

1. Initial and final plasma conductivity, as displayed by the Diascan monitoring tool, recorded in all mid-week dialysis sessions during the 6 week study period
2. Body weight post-dialysis for all mid-week dialysis sessions and pre-dialysis for all subsequent dialysis sessions during the 6 week study period

Secondary outcome measures

1. Initial and final plasma conductivity levels during the dialysis session
2. Plasma sodium levels pre- and post-dialysis
3. Plasma osmolarity level pre- and post-dialysis
4. Intradialytic change in plasma sodium
5. Dialysis fluid to plasma sodium gradient at start of dialysis
6. Body weight pre and post dialysis and pre dialysis at the following dialysis session
7. Need for saline infusion (isotonic saline or hypertonic solution) during the dialysis session
8. Recording of potential safety events

Overall trial start date

29/01/2013

Overall trial end date

30/06/2013

Reason abandoned

Eligibility

Participant inclusion criteria

1. End stage renal disease (ESRD)
2. Male and female aged 18 years or older
3. Treated in HD or HemoDiaFiltration (HDF) mode three times per week since at least 3 months
4. On stable dialysis prescription since at least 1 month (without major changes in dry weight, dialysis fluid conductivity/sodium level, dialyzer type, blood flow rate)
5. Available for treatment with Gambro dialysis machines equipped with the Diascan monitoring tool
6. Signed consent to participate in the study (informed consent)

Participant type

Patient

Age group

Adult

Gender

Both

Target number of participants

230

Participant exclusion criteria

1. 24 hour urine volume production estimated to be >100 ml
2. Dialysis prescribed with varying dialysate sodium level (sodium profiling)
3. Considered unable to respond to thirst by free fluid intake
4. Regularly prescribed infusion of Na-containing fluids during or between dialysis session (e.g. saline to manage intradialytic hypotension)
5. Regularly prescribed infusion of albumin solution, e.g. to manage hypoalbuminemia or intradialytic hypotension
6. Pregnancy or planned pregnancy
7. Known hyperproteinemia or hyperlipidemia

Recruitment start date

29/01/2013

Recruitment end date

30/06/2013

Locations

Countries of recruitment

Korea, South

Trial participating centre

Samsung Medical Center
Seoul
135-710
Korea, South

Sponsor information

Organisation

Gambro Korea Ltd. (Korea, South)

Sponsor details

c/o Jungmin Im
Head Office
4F KLC Building,145-9 Samseong-dong
Gangnam-gu
Seoul
135-090
Korea
South

Sponsor type

Industry

Website

http://www.gambro.com

Funders

Funder type

Industry

Funder name

Gambro Korea Ltd. (Korea, South)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes